Charles River Laboratories' Automation Improves Manufacturing Metrics Amid Margin Challenges
On September 8, Charles River Laboratories (NYSE:CRL) announced that its automated cartridge manufacturing suite for Endosafe endotoxin testing reached full operational capacity in the third quarter. The automation has led to measurable improvements: a 2% reduction in scrap rates, a 13% drop in invalid cartridges, and an 87% increase in labor productivity. These gains are reflected in improved non-GAAP operating margins for its Manufacturing segment, which rose from 32.8% to 37.8%, alongside organic revenue growth of 1.3%. The company also raised full-year guidance due to strong performance in the Microbial Solutions business and new partnerships with firms like Eli Lilly. Despite these operational successes, Charles River's overall financial results remain mixed. In Q2 2026, it reported a GAAP loss per share of $0.03 compared to earnings of $1.06 per share in the prior year, largely due to losses from divestitures. Total revenue declined by 2.7% YoY to $1 billion, and non-GAAP operating margin fell slightly to 20.5%. The Discovery and Safety Assessment segment saw a drop in margins despite improved study volume, while Research Models and Services continued to decline as demand for small research models softened. The stock currently trades at a forward P/E of 22.47 with rising hedge fund ownership but also notable short interest (6.14% of float). The market appears divided on whether the company's automation-driven improvements will overcome ongoing margin pressures.
Topics: automation manufacturing efficiency operating margins revenue growth